Key Clinical Message
The risk of secondary malignancies due to TKIs is a growing concern.
There remains no consensus on the management of secondary lymphoma
during TKI therapies. The only alternative is to observe patients
receiving TKI treatment cautiously and to treat in the same manner as de
novo lymphoma.